Could a smartphone replace clinic visits for rare tumor survivors?

NCT ID NCT04573816

Completed Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study tests whether a remote monitoring program can reliably track the health of people who have had surgery for pheochromocytoma or paraganglioma (PPGL), rare adrenal tumors. Participants use an internet platform to report their data, which is compared to information collected during in-person clinic visits. The goal is to see if remote monitoring can be as reliable as standard follow-up care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If reliable, this remote monitoring program could reduce the need for frequent in-person clinic visits for patients with these rare tumors.
What could go wrong: The study is small and single-center, so results may not apply broadly. It only measures reliability of data collection, not long-term health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARAGANGLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

paraganglioma pheochromocytoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARAGANGLIOMA PHEOCHROMOCYTOMA

Contacts and locations

Show contact details

Locations

Hopital européen Georges Pompidou

Paris, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.